Physician profile
Stephen Toadvine
NPI 1356314199
$760.66
in general payments reported to CMS, 2019-2025
17 companies · $636 in 2025
The $636 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.45 · 2024: $97.08 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $733.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $170.96 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $134.90 | 2025 | Fanapt, Hetlioz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.11 | 2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $42.44 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.73 | 2025 | Caplyta |
| Abbott Laboratories | $36.60 | 2024 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $35.20 | 2025 | Austedo Xr |
| Glaxosmithkline, LLC. | $28.98 | 2025 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $25.84 | 2025 | |
| Novo Nordisk INC | $17.88 | 2025 | |
| Neurocrine Biosciences, INC. | $17.85 | 2025 | |
| Insulet Corporation | $16.42 | 2025 | Omnipod |
| Jazz Pharmaceuticals INC. | $15.95 | 2019 | |
| Merck Sharp & Dohme LLC | $15.84 | 2024 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Gilead Sciences, INC. | $13.85 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $13.61 | 2025 | Dexcom G6 Transmitter |
| Philips North America LLC | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Toadvine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.